FTAI Aviation Ltd vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? FTAI Aviation Ltd trades at $169.46 (market cap $17.57B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.71 (market cap $2.27B). The key difference: FTAI Aviation Ltd is far larger — about 7.7× SELLAS Life Sciences Group Inc. Common Stock's market cap, and FTAI Aviation Ltd pays a 1.17% dividend while SELLAS Life Sciences Group Inc. Common Stock pays none. Which is the better fit depends on your goals.
| FTAI | SLS | |
|---|---|---|
Market Cap | $17.57B | $2.27B |
Volume | 1,905,014 | 4,179,659 |
Sector | Industrials | Health |
52-Week High | $310.04 | $15.46 |
52-Week Low | $152.80 | $1.39 |
Typical Hold Time | 23 Days | — |
Enterprise Value | $20.69B | $2.14B |
Dividend Yield | 1.17% | — |
Signals from Pluang's Aura AI — not financial advice
FTAI Aviation trades at $169.47, down 3.07% today, with a bearish technical signal from moving averages. The company reported strong 2025 revenue of $2.51B and net income of $501M, though recent quarters have missed EPS expectations. Recent developments include a $500M share buyback program and a strategic acquisition of 27 Boeing aircraft, signaling growth focus. Analyst consensus remains unanimously bullish with a $321.25 price target, highlighting institutional confidence despite near-term earnings volatility.
The outlook for FTAI is positive based on robust analyst support and strategic expansions, but risks include consecutive EPS misses and a high P/E ratio of 37.35. Investors face volatility from operational cash flow challenges and competitive pressures in the aviation sector, though the buyback and new partnerships provide catalysts for recovery.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
FTAI Aviation owns and maintains a fleet of commercial aircraft and engines. It focuses on the specialized maintenance of the CFM56 engine, helping airlines reduce costs through efficient asset management.
Read more on FTAI →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →